Outlook Therapeutics Inc (OTLK) Stock Analysis

AI analysis of Outlook Therapeutics Inc (OTLK)

Hold

Outlook Therapeutics Inc (OTLK) is currently trading at $0.4692, significantly below its 52-week high of $2.54, indicating a potential for recovery. However, the stock has a low RSI of 31.097, suggesting it is oversold but also reflects ongoing bearish sentiment. The company has reported a net loss of $20.3 million in Q3 2026, and its gross margin has plummeted to -95% in the same quarter, which raises concerns about financial stability. Despite the positive catalyst of FDA approval for LYTENAVA, the current financial performance and high volatility suggest caution. The main risk is the ongoing losses, with a net margin of -233554.85%.

Valuation Metrics

The current forward P/E ratio for Outlook Therapeutics Inc (OTLK) is 2.85, compared to its 5-year average forward P/E of -2.38.

Forward P/E

Overvalued

5Y Average P/E

-2.38

Current P/E

2.85

Overvalued

0.96

Undervalued

-5.71

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-1.25

Current EV/EBITDA

0.00

Overvalued

11.45

Undervalued

-13.95

Forward P/S

Fair

5Y Average P/S

198.31

Current P/S

2.55

Overvalued

654.50

Undervalued

-257.87

OTLK FAQ — answered by Alphio AI

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Outlook Therapeutics Inc (OTLK) is currently trading at $0.4692, significantly below its 52-week high of $2.54, indicating a potential for recovery. However, the stock has a low RSI of 31.097, suggesting it is oversold but also reflects ongoing bearish sentiment. The company has reported a net loss of $20.3 million in Q3 2026, and its gross margin has plummeted to -95% in the same quarter, which raises concerns about financial stability. Despite the positive catalyst of FDA approval for LYTENAVA, the current financial performance and high volatility suggest caution. The main risk is the ongoing losses, with a net margin of -233554.85%.